# IGC Pharma, Inc. (IGC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IGC
## Company Profile
- Ticker: IGC
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 0.2985 USD
- Market cap: 29026481.93 USD
- Last updated: 2026-09-03
## Business Overview
IGC Pharma is a biopharmaceutical company exploring cannabinoid-based and other therapeutic programs, including neuropsychiatric and metabolic concepts. Its identity has been tied to a broad but still early-stage development story.
## Why The Stock Is Moving

As of Sep 3, 2026, IGC closed up 0.88% at $0.2985. No new same-company headline was identified in the current news window.

## Geographic Base

IGC Pharma is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotech with a neuropsychiatry and cannabinoid angle.

## Business Model

The company depends on early development work, regulatory pathfinding, and capital efficiency. Investors typically watch program updates, preclinical or early clinical signals, and whether the company can sharpen its focus.

## Landscape Position

IGC occupies a speculative small-cap biotechnology niche. It is more of an early-stage concept story than a mature clinical platform.

## Future Catalysts

- IGC Pharma’s catalysts are its cannabis-derived and neuro-related programs, plus any operating update that clarifies commercial progress. The market will care about whether the company can turn the platform into a real business.

## Recent News
- 2023-03-20 12:45 EST — [IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.](https://biopharmsignal.com/news/IGC/igc-announces-rebranding-changes-name-to-igc-pharma-inc-900130c9) — Source: IGC Pharma, Inc.
- 2023-02-15 00:41 EST — [IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022](https://biopharmsignal.com/news/IGC/igc-reports-financial-results-for-third-fiscal-quarter-ended-dec-31-2022-bf21b08c) — Source: IGC Pharma, Inc.
- 2023-02-08 13:30 EST — [IGC to be Featured in Feb. 10 Radius Research Investor Webinar](https://biopharmsignal.com/news/IGC/igc-to-be-featured-in-feb-10-radius-research-investor-webinar-a2840285) — Source: IGC Pharma, Inc.
- 2023-01-04 13:00 EST — [IGC Receives No Objection Letter from Health Canada](https://biopharmsignal.com/news/IGC/igc-receives-no-objection-letter-from-health-canada-c886cb01) — Source: IGC Pharma, Inc.
- 2022-12-20 13:30 EST — [IGC Announces Updated Life Sciences Presentation](https://biopharmsignal.com/news/IGC/igc-announces-updated-life-sciences-presentation-d5fae0ed) — Source: IGC Pharma, Inc.